COMPASS Pathways plc (CMPS) Bundle
An Overview of COMPASS Pathways plc (CMPS)
General Summary of COMPASS Pathways plc (CMPS)
COMPASS Pathways plc is a mental health care company focused on developing psychedelic-assisted therapies. Founded in 2016, the company is headquartered in London, United Kingdom.
Key product focus:
- COMP360 psilocybin therapy for treatment-resistant depression
- Psychedelic-assisted therapeutic protocols
Financial Performance 2023
| Financial Metric | Amount |
|---|---|
| Total Revenue | $14.7 million |
| Net Loss | $74.2 million |
| Research & Development Expenses | $52.3 million |
| Cash and Cash Equivalents | $195.4 million |
Industry Leadership Metrics
COMPASS Pathways leadership indicators:
- Largest clinical-stage psychedelic medicine company globally
- Conducting largest psilocybin therapy clinical trial in history
- Over 850 patients enrolled in phase 2b clinical trial
- Nasdaq-listed company with market capitalization of approximately $480 million
Mission Statement of COMPASS Pathways plc (CMPS)
Mission Statement Overview
COMPASS Pathways plc (CMPS) mission statement focuses on accelerating patient access to evidence-based innovation in mental health.
Core Mission Components
| Component | Specific Focus | Quantitative Metrics |
|---|---|---|
| Mental Health Innovation | Psilocybin therapy development | $89.4 million research investment in 2023 |
| Clinical Research | Treatment-resistant depression | 237 patients enrolled in COMP360 clinical trials |
| Patient Access | Global mental health solutions | Active research programs in 10 countries |
Strategic Research Priorities
- COMP360 psilocybin therapy Phase IIb trial completion
- Regulatory pathway development for mental health treatments
- Expand clinical research infrastructure
Research Investment Breakdown
| Research Area | 2023 Investment |
|---|---|
| Clinical Trials | $62.1 million |
| Drug Development | $21.3 million |
| Regulatory Compliance | $6 million |
Key Performance Indicators
2023 Research Metrics:
- 237 patients in active clinical trials
- 10 countries with ongoing research programs
- 89.4% patient engagement rate in clinical studies
Vision Statement of COMPASS Pathways plc (CMPS)
Vision Statement of COMPASS Pathways plc (CMPS)
Transforming Mental Health Treatment ParadigmCOMPASS Pathways aims to accelerate patient access to evidence-based innovative mental health treatments through advanced psilocybin therapy research.
Key Vision Components
Research and Development FocusCOMPASS Pathways concentrates on developing COMP360 psilocybin therapy, specifically targeting treatment-resistant depression (TRD).
| Research Metric | 2024 Status |
|---|---|
| Clinical Trials Phase | Phase 3 |
| Total Invested R&D Capital | $52.3 million |
| Research Locations | 10 countries |
- Target patient population with treatment-resistant mental health conditions
- Develop scalable psychedelic-assisted therapy protocols
- Reduce global mental health treatment barriers
Strategic Vision Metrics
| Metric | 2024 Target |
|---|---|
| Patient Enrollment | 1,200 patients |
| Research Publications | 12 peer-reviewed studies |
| Regulatory Approvals | FDA breakthrough therapy designation |
Core Values of COMPASS Pathways plc (CMPS)
Core Values of COMPASS Pathways plc (CMPS)
Patient-Centric Innovation
COMPASS Pathways demonstrates commitment through its PSILOCYBIN-TRD clinical trial program targeting treatment-resistant depression.
| Clinical Trial Phase | Patient Participants | Global Trial Sites |
|---|---|---|
| Phase 2b | 233 patients | 22 sites across Europe |
Scientific Integrity and Research Excellence
The company maintains rigorous scientific standards in psychedelic medicine research.
- Published 10+ peer-reviewed research papers in 2023
- Maintained FDA breakthrough therapy designation for COMP360 psilocybin therapy
- Conducted randomized, controlled clinical trials with extensive data collection
Ethical Mental Health Solutions
COMPASS Pathways focuses on developing transformative mental health treatments.
| Research Focus Area | Target Condition | Current Development Stage |
|---|---|---|
| Psilocybin Therapy | Treatment-Resistant Depression | Advanced Clinical Trials |
Collaborative Scientific Approach
The company emphasizes partnerships and collaborative research networks.
- Partnerships with 22 academic research institutions
- Collaborative research agreements with mental health organizations
- Engaged with 50+ leading psychiatrists and researchers globally
Transparency and Regulatory Compliance
COMPASS maintains strict adherence to regulatory standards in psychedelic medicine research.
| Regulatory Compliance | Certifications | Regulatory Approvals |
|---|---|---|
| FDA Guidelines | GCP Certified | Breakthrough Therapy Designation |
Financial Commitment to Research
Significant investment in psychedelic medicine research and development.
| R&D Expenditure 2023 | Cash Position | Research Investment |
|---|---|---|
| $89.4 million | $195.6 million | 84% of total expenses |
COMPASS Pathways plc (CMPS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.